Summary

New data from the RICMAC trial showed similar rates of non-relapse mortality, incidence of relapse, and relapse-free survival in patients with myelodysplastic syndrome or secondary acute myeloid leukemia after conditioning with reduced-dose busulfan plus fludarabine vs standard-dose busulfan plus cyclophosphamide prior to allogeneic stem cell transplantation. Overall survival was higher with the reduced dose, but results were not statistically significant.